8 February 2022 - Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10%.

NICE has today issued draft guidance recommending semaglutide (Wegovy, Novo Nordisk) to adults with at least one weight-related condition and a body mass index of at least 35 kg/m2, and exceptionally, to people with a BMI of 30.0 kg/m2 to 34.9 kg/m2.

Read NICE press release